NVO·Healthcare·Pharma
Novo Nordisk Wegovy Strategy +2.9% Rally After 70% Slide
Can the aggressive Novo Nordisk Wegovy Strategy subscription push really reverse a 70% stock slide and close the gap to…
Healthcare
NVO·Healthcare·Pharma
ABBV·Healthcare·Dividend Aristocrats
AbbVie Dermatology Data Boom at AAD 2026 Shocks Investors
Can AbbVie’s latest dermatology data at AAD 2026 really secure its post-Humira growth story in immunology? Maik Kemper Editor in…
HIMS·Healthcare
Hims & Hers GLP-1 partnership sparks new weight-loss boom
Can the Hims & Hers GLP-1 partnership with Novo Nordisk turn telehealth weight loss into the company’s next major growth…
MRK.DE·Healthcare
Merck Terns Acquisition $6.7B Surge as Keytruda Cliff Nears
Can the Merck Terns Acquisition really plug the looming Keytruda revenue gap or is $6.7 billion just a high-risk oncology…
LLY·Healthcare·Pharma
Eli Lilly GLP-1 Strategy Boom and Revenue Shock
Can Eli Lilly’s GLP-1 boom keep powering the stock as regulation, lawsuits and ETF concentration risks close in? Maik Kemper…
PFE·Healthcare·Pharma
Pfizer Lyme vaccine 70% efficacy Shock as PFE slips
Can the Pfizer Lyme vaccine’s >70% efficacy data revive sentiment around PFE just as investors write off its post-COVID growth…
LLY·Healthcare·Pharma
Eli Lilly Retatrutide Boom: Triple-Agonist Trial Shock
Can Eli Lilly Retatrutide’s powerful Phase 3 diabetes data reignite confidence in the GLP-1 boom despite rising competitive and pricing…
LLY·Healthcare·Pharma
Eli Lilly Forecast Warning after HSBC’s bearish reset
Is the latest bearish Eli Lilly Forecast a rare buying opportunity or the start of a painful valuation reset in…
JNJ·Healthcare·Dividend Aristocrats
Johnson & Johnson FDA approval ICOTYDE Boom Explained
Can Johnson & Johnson’s FDA approval of ICOTYDE really shift the psoriasis market enough to move a $575 billion healthcare…
HIMS·Healthcare
Hims & Hers insider transactions Warning as GLP-1 bets grow
Are Hims & Hers insider transactions hinting at caution just as the company doubles down on its high-stakes GLP-1 obesity…